Association between Overall Survival and Activities of Daily Living in Patients with Spinal Bone Metastases

Yoshiteru Akezaki, Eiji Nakata, Masato Kikuuchi, Shinsuke Sugihara, Yoshimi Katayama, Haruyoshi Katayama, Michiaki Hamada, Toshifumi OzakiHealthcare 2022 · DOI

TL;DR

This study reveals that a patient's ability to perform daily activities (ADL), their primary cancer type, and their treatment strategy are significant predictors of overall survival (OS) in patients with spinal bone metastases. The findings suggest that maintaining and improving ADL through rehabilitation, alongside timely treatment adjustments, could positively impact survival outcomes.

What Problem Does This Paper Address?

Spinal bone metastases are a common and serious complication of cancer, leading to skeletal-related events (SREs) like pain, fractures, and spinal cord compression. While treatments like radiotherapy, chemotherapy, and surgery aim to manage these complications and improve quality of life, understanding the factors that influence long-term survival in these patients remains crucial for effective medical care. Previous research has identified factors like performance status and tumor type, but the specific role of Activities of Daily Living (ADL) in predicting overall survival (OS) in this population has been less explored. This paper aims to fill that gap by investigating the association between ADL and OS in patients with spinal bone metastases who have experienced SREs.

Methods

This study employed a retrospective observational design. The researchers analyzed data from 265 patients who presented with SREs and underwent radiotherapy for spinal bone metastases between 2012 and 2016. They collected clinical parameters including age, sex, comorbidities, ADL (measured by the Barthel index), pain levels, primary cancer site, spinal level of metastases, spinal instability, and treatment strategy (chemotherapy or palliative care).

Key methodological points:

  • ADL Measurement: The Barthel index was used, with scores ≥90 classified as "high ADL" and <90 as "low ADL." This is a standard measure for assessing functional independence.
  • Overall Survival (OS) Definition: Patients surviving ≥160 days were categorized as "non-poor prognosis," and those surviving <160 days as "poor prognosis." This cutoff was based on the median survival time.
  • Statistical Analysis: Univariate analyses (chi-squared and Mann-Whitney U tests) were used to identify potential predictors. Significant factors (p < 0.1) were then subjected to multiple logistic regression to pinpoint independent predictors of OS. Kaplan-Meier survival analysis and log-rank tests were used to compare survival curves.

Datasets

The study utilized data from 265 patients treated at a single tertiary institution in Japan between 2012 and 2016. This dataset comprised clinical parameters collected before radiotherapy for SREs. No new benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • ADL as a Strong Predictor: The most striking finding is the significant association between a patient's ADL status and their overall survival. This highlights that functional independence is not just about quality of life but also a critical indicator of prognosis in this patient group.
  • Cancer Type Matters: The primary site of cancer is also a significant predictor, with breast cancer showing a more favorable impact on survival compared to other cancer types. This aligns with existing knowledge about the generally better prognosis of breast cancer.
  • Treatment Strategy's Impact: The choice of treatment strategy—specifically, chemotherapy versus palliative care—demonstrates a substantial difference in survival outcomes. This suggests that aggressive treatment, when appropriate, can extend life.
  • Interconnectedness of Factors: The study emphasizes that these factors (ADL, primary site, treatment) are not isolated but work together to influence survival. This calls for a holistic approach to patient management.

Key Results

  • Significant Predictors: Multiple logistic regression analysis identified ADL, primary site, and treatment strategy as significant predictors of OS (p < 0.05).
  • Positive Impact: High ADL, breast cancer as the primary site, and chemotherapy treatment all had a positive effect on OS.
  • Univariate Differences: In univariate analysis, age, sex, ADL, pain, primary site, and treatment strategy showed significant differences between the non-poor and poor prognosis groups (p < 0.1).
  • ADL Group Differences: The high ADL group had significantly better survival rates than the low ADL group (p = 0.001).
  • Primary Site Differences: Breast cancer patients had significantly better survival than patients with other cancer types (p < 0.0001).
  • Treatment Strategy Differences: Patients receiving chemotherapy had significantly better survival than those receiving palliative treatment (p < 0.0001).
  • Barthel Index and Treatment: The Barthel index was significantly lower in the palliative treatment group compared to the chemotherapy group (p < 0.05), suggesting that patients receiving palliative care may have had lower baseline functional status.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature introduces potential biases inherent in analyzing existing data.
  • Sample Size and Heterogeneity: While 265 patients is a reasonable number, the study included various cancer types and treatment regimens, which can introduce variability.
  • Limited Physical Function Evaluation: The study did not evaluate specific physical functions like muscle strength, skeletal muscle mass, or balance. These factors could also influence survival and were not accounted for.

Future work suggested by the authors includes:

  • Developing rehabilitation interventions to maintain and improve ADL.
  • Establishing systems for monitoring spinal bone metastases using imaging to detect changes before significant ADL decline.
  • Implementing timely adjustments to treatment methods (e.g., RT, surgery) when necessary.
  • Further research to explore the impact of specific physical functions on survival outcomes.

Summary updated

Abstract

<i>Objective:</i> This study aimed to investigate the association between overall survival (OS) and activities of daily living (ADL) in patients with skeletal-related events. In this study, 265 patients whose clinical parameters were available before radiotherapy were investigated. <i>Methods:</i> Age, sex, ADL, pain, the primary site, spinal level of bone metastases, spinal instability, treatment strategy, including chemotherapy or palliative treatment, and OS were investigated. ADL patients with a Barthel index of ≥90 were classified as the high ADL group, while those with a score < 90 were classified as the low ADL group. For OS, patients surviving ≥160 days were classified as the non-poor prognosis group, and those who survived <160 days were classified as the poor prognosis group. <i>Results:</i> Age, sex, ADL, pain, the primary site, and treatment strategy for OS were different between the two groups (<i>p</i> < 0.1). Logistic regression analysis revealed that ADL, the primary site, and treatment strategy were significant predictors of OS (<i>p</i> < 0.05). High ADL, breast cancer, and chemotherapy had a positive effect on OS. <i>Conclusions:</i> It is suggested that improvements may be obtained by performing rehabilitation interventions to maintain and improve ADL, by constructing a system for monitoring spinal bone metastases with images before ADL decreases, and by performing interventions such as changes in treatment methods such as RT or surgery at appropriate times.
BibTeX
@inproceedings{akezaki2022association,
  author = {Yoshiteru Akezaki and Eiji Nakata and Masato Kikuuchi and Shinsuke Sugihara and Yoshimi Katayama and Haruyoshi Katayama and Michiaki Hamada and Toshifumi Ozaki},
  title = {{Association between Overall Survival and Activities of Daily Living in Patients with Spinal Bone Metastases}},
  booktitle = {Healthcare},
  year = {2022},
  doi = {10.3390/healthcare10020350},
}
Figure